Dicyclomine Hydrochloride Capsules, 10mg recall — Aurobindo Pharma Usa Inc (Class II)

Aurobindo Pharma Usa Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Dicyclomine Hydrochloride Capsules, 10mg — a Class II recall, initiated 2026-07-23 and posted to the FDA enforcement report on 2026-08-12, under recall number D-0733-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “shortfill; reports of empty capsules.”. From the product description, the form is capsules, the strength given is 10mg, the package is described as 1,000 bottles and it is marked Rx only. 1 National Drug Code number is printed in the record: 59651-719-99. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99492. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0733-2026
FDA event ID 99492
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Aurobindo Pharma Usa Inc
Recall initiated 2026-07-23
Reported by FDA 2026-08-12
Report lag 20 days from initiation to report
Distribution US Nationwide. — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-719-99

Reason reported by FDA

shortfill; reports of empty capsules.

5 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 27-word product description above; each is a literal substring of it.

Product named Dicyclomine Hydrochloride Capsules
Form Capsules
Strength 10mg
Package 1,000 bottles
NDC 59651-719-99
Marketing category Rx only
Stated origin India
Distributed by Aurobindo Pharma USA, Inc.

Reported in the same month (2026-08)

11 enforcement reports carry a report date in 2026-08; these 4 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Mirabegron Extended-Release Tablets, 25 mgD-0745-2026Zydus Pharmaceuticals (usa) IncClass II2026-08-12
Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2%/0.5%D-0730-2026Micro Labs Usa IncClass II2026-08-05
Azelaic Acid Gel, 15%D-0731-2026Glenmark Pharmaceuticals Inc., UsaClass II2026-08-05
Mycophenolate Mofetil for Injection USP, 500 mg/VialD-0734-2026Mylan Pharmaceuticals IncClass II2026-08-05

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 10 nearest to 2026-08-12 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Levothyroxine Sodium Tablets, 25 mcgD-0700-2026Major Pharmaceuticals25 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0701-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0702-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 88 mcgD-0703-2026Major Pharmaceuticals88 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 112 mcgD-0704-2026Major Pharmaceuticals112 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0705-2026Major Pharmaceuticals125 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0706-2026Major Pharmaceuticals150 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 25 mcgD-0707-2026Major Pharmaceuticals25 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0708-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0709-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 59651-719-99 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Aurobindo Pharma Usa Inc (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0733-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0733-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-08-12
Ingested
2026-08-22
Record hash
859acb0fd5aa4b77

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.